Cycle on Aug 3, 2026

I will start by retrieving the open threads and existing notes for the GLP-1 research topic to understand what has been tracked so far and identify any specific questions or watches that need attention.

I will list the existing notes for the GLP-1 research topic to see what has already been written and identify which notes to update.

I see several open watch threads that are highly relevant to this cycle's current date (August 3, 2026): 1. Viking Therapeutics Q2 2026 Earnings Call and Corporate Update (fire_date: July 30, 2026) -> `019fa2b2-744d-7bfb-aced-a1ebd4550e8c` 2. Novo Nordisk Q2 2026 Earnings and Oral Wegovy Retention Rates (fire_date: August 5, 2026) -> `019f5a99-5df2-79a6-a479-7bd5b7c92acd` - This is coming up in 2 days. Let's see if there is any preview, or maybe it hasn't happened yet. 3. Eli Lilly Patent Infringement Lawsuits against Sandoz and Hybio (Tirzepatide ANDAs) (fire_date: August 15, 2026) -> `019f7ea7-f526-7381-8937-a067d41f8465` - Let's see if Eli Lilly has filed lawsuits against Sandoz and Hybio yet. 4. Preliminary Injunction Decision in Novo Nordisk v. Eli Lilly False Advertising Lawsuit (fire_date: August 31, 2026) -> `019fa2b2-30f2-7453-a82b-71b8bf637885` - Let's check the status of this lawsuit. Let's do some search queries to see what's happened in the last week or two regarding these topics. First, let's look at Viking Therapeutics (VKTX) Q2 2026 earnings. They reported on July 29, 2026. Let's search for "Viking Therapeutics Q2 2026 earnings" or "Viking Therapeutics oral VK2735 Phase 3". Let's also search for "Eli Lilly lawsuit Sandoz Hybio tirzepatide". Let's search for "Novo Nordisk Eli Lilly lawsuit preliminary injunction". Let's search for "Novo Nordisk Q2 2026 earnings" to see if there is any early news or preview. Let's start with Viking Therapeutics. I will state my intent and run a web search.

This is excellent. We have the Q2 2026 earnings results for Viking Therapeutics (reported July 29, 2026). Let's fetch the stocktitan press release or the transcript to find the exact details. Let's see if we can search for the stocktitan URL or search specifically for the press release text to get the actual numbers/quotes. Let's use `web_fetch` on `https://www.stocktitan.net/news/VKTX/viking-therapeutics-reports-second-quarter-2026-financial-results-t0xbdsxl83j8.html` first. Then we'll search for the transcript or details of the earnings call.

This gives us some excellent facts. First, Viking reported that: 1. Phase 3 VANQUISH-1 (subcutaneous VK2735 in obesity, ~4,500 patients) is **fully enrolled**. 2. Phase 3 VANQUISH-2 (subcutaneous VK2735 in obesity with type 2 diabetes, ~1,000 patients) is **fully enrolled**. 3. They are preparing to initiate Phase 3 trials of **oral VK2735** for obesity in **4Q26**. 4. They expect data from a Phase 1 VK2735 maintenance dosing study in **3Q26** (specifically, "later this quarter", which is Q3 2026). 5. They have initiated a Phase 1 single ascending dose trial of obesity candidate **VK3019** (an amylin receptor agonist) in Q2 2026. 6. Cash balance is **$502 million** at June 30, 2026, down from $706 million at Dec 31, 2025. 7. Q2 net loss was $128.0M ($1.10/share) vs $65.6M ($0.58/share) in Q2 2025, driven by higher R&D expenses ($115.8M vs $60.2M). This directly addresses several watches: - `019fa2b2-744d-7bfb-aced-a1ebd4550e8c` (Viking Therapeutics Q2 2026 Earnings Call and Corporate Update) - This watch can be resolved since the earnings call and update happened. - `019f5a99-679f-7247-9705-ad3f8b2ad4cd` (Viking Therapeutics Oral VK2735 Phase 3 Trial Initiation) - They reaffirmed they plan to start this in 4Q26. This watch is for the actual initiation, so we keep it open or we can update it if we need to. Since it's a future event, we keep it open. - `019f7ea7-feb9-7623-b860-3dba62bb1602` (Viking Therapeutics VK2735 Phase 1 Maintenance Dosing Results) - They reaffirmed they expect results "later this quarter" (3Q26). This watch stays open. Let's record the event for watch `019fa2b2-744d-7bfb-aced-a1ebd4550e8c` (Viking Therapeutics Q2 2026 Earnings Call and Corporate Update). Wait, let's first search for more info about the other watches to see what else we can find. Let's search for "Eli Lilly lawsuit Sandoz Hybio tirzepatide" to see if Eli Lilly has filed lawsuits. Sandoz and Hybio had their tirzepatide ANDAs accepted in late June 2026, and Lilly had 45 days to file patent infringement lawsuits to trigger the 30-month automatic stay. Let's see if those lawsuits have been filed. Sandoz and Hybio's ANDA acceptances were late June 2026, so 45 days would put the deadline around mid-August 2026. Let's see if Lilly has filed them.

Let's search for court dockets or news on Eli Lilly filing patent infringement lawsuits against Sandoz or Hybio in July or August 2026. Let's search for: `site:docketalarm.com "Eli Lilly" AND "Sandoz" AND "tirzepatide"` or `site:justia.com "Eli Lilly" AND "Sandoz"` or search more broadly: `"Eli Lilly" AND "Sandoz" AND "tirzepatide" AND "patent"`. Let's run a web search.

Let's search more specifically for the filing of the patent infringement lawsuit. Since the ANDA acceptance was late June (around June 29-30, 2026), Eli Lilly has 45 days to sue. 45 days from June 30 is August 14, 2026. Let's see if Eli Lilly has already filed any lawsuits in July or August 2026 against Sandoz or Hybio. Let's do a search for: `"Eli Lilly" AND "Sandoz" AND (lawsuit OR filed OR complaint OR patent)`. Let's also search `"Eli Lilly" AND "Hybio"`. Let's run a web search.

Let's fetch the Parola Analytics article: `https://parolaanalytics.com/parolanews/sandoz-generic-filing-tirzepatide-eli-lilly-patent-cliff/` to see if there is any mention of a lawsuit or details. Let's do a web_fetch.

This is a very detailed article about Sandoz's ANDA filing on July 15, 2026. Note that the article was published on July 15, 2026, and mentions that the FDA accepted the ANDAs. Let's see if there is any update on whether Eli Lilly has actually filed a patent infringement lawsuit. Sandoz's ANDA was accepted in late June (or mid-July as this article says, wait, "The U.S. Food and Drug Administration has accepted two Abbreviated New Drug Applications (ANDAs) from Sandoz for proposed generic tirzepatide autoinjectors" and the article is dated July 15, 2026). Let's do a search on PACER or a broad search for court cases: `"Eli Lilly" AND "Sandoz" AND "tirzepatide"` or `"Eli Lilly" AND "Hybio" AND "tirzepatide"`. Let's run a web search.

Let's fetch the Life Sciences IP Review article: `https://www.lifesciencesipreview.com/americas/will-mounjaro-and-zepbound-get-their-first-us-generic-rival` to see if there is any mention of a lawsuit or if they discuss the 45-day window. Let's do a web_fetch.

Ah, it's behind a paywall. Let's search for "Eli Lilly files patent lawsuit against Sandoz" or "Eli Lilly sues Sandoz tirzepatide" on Google or specialized legal news sites. Let's run a web search.

Let's search for "Eli Lilly" AND "Sandoz" AND "tirzepatide" on Google News (freshness="month") to see if there's any recent news of a lawsuit filed in the last month. We can also search for Hybio. Let's run a web search.

Ah! Let's look at this Reuters news from July 24, 2026: "Novo Nordisk pursues preliminary injunction to block Eli Lilly weight-loss drug ads". Let's fetch that page. This is extremely relevant to our watch `019fa2b2-30f2-7453-a82b-71b8bf637885` (Preliminary Injunction Decision in Novo Nordisk v. Eli Lilly False Advertising Lawsuit). The watch description says: "Novo Nordisk plans to file a formal motion for a preliminary injunction on August 17, 2026, to stop Eli Lilly from running comparative ads for Zepbound and Mounjaro." Wait, let's read the Reuters article to see if Novo Nordisk has already filed or if they are planning to do so or if they filed something early. Let's run a `web_fetch` on `https://www.reuters.com/world/novo-nordisk-seeks-preliminary-injunction-against-lilly-weight-loss-ads-2026-07-24/`.

This is very useful. Let's note that Novo Nordisk officially filed the motion for a preliminary injunction on Friday, July 24, 2026, following its initial lawsuit on Tuesday, July 21, 2026. This is a key step in the ongoing Lanham Act false advertising lawsuit (`novo-sues-lilly-false-advertising-glp1-2026`). Let's see if we can find more details about this lawsuit or if there is any scheduled date for the preliminary injunction hearing or decision. Wait, let's search for "Novo Nordisk Eli Lilly lawsuit preliminary injunction hearing date" or look up court dockets for the District of New Jersey case (filed July 21, 2026). Let's run a web search.

Let's fetch the PDF of the complaint if possible, or search for "NovoNordiskIncvEliLillyandCompanyComplaint072726.pdf" to get the exact arguments, or let's read the Law.com article: `https://www.law.com/njlawjournal/2026/07/27/novos-bid-to-halt-lilly-ads-tests-how-long-drugmakers-can-rely-on-older-clinical-trials/`. Let's first fetch the PDF of the complaint: `https://business.cch.com/ald/NovoNordiskIncvEliLillyandCompanyComplaint072726.pdf`. Wait! Let's see if the tool `web_fetch` can read PDFs. Yes, it returns markdown, which might extract the text or some of it. Let's try it.

This is an absolute goldmine! We have the full, exact complaint filed on July 21, 2026, in the District of New Jersey, Case 3:26-cv-09027-ZNQ-RLS (Novo Nordisk Inc. v. Eli Lilly and Company and Lilly USA, LLC). Let's see what the main points are: 1. **Zepbound vs. Wegovy**: Novo Nordisk claims Eli Lilly's ads are false because they cite outdated trials (SURMOUNT-5, open-label, published May 2025) comparing Zepbound 10mg and 15mg (maximum tolerated doses) with Wegovy 1.7mg and 2.4mg (max tolerated doses at the time). However, in March 2026, the FDA approved **Wegovy 7.2 mg** (supported by the STEP UP trial showing 18.8% average weight loss or 47 lbs, clinically consistent with Zepbound 15mg's 20.9% or 48 lbs in SURMOUNT-1). Lilly revised the ad to state "Wegovy 7.2 mg was not evaluated in this study. It has since been approved" in a small footnote, but Novo claims this is inadequate. 2. **Mounjaro vs. Ozempic**: Lilly's ads compare Mounjaro 15mg (2.3% HbA1c reduction) to Ozempic 1mg (1.9% reduction) based on the 5-year-old SURPASS-2 trial. However, the FDA approved **Ozempic 2 mg** in 2022 (supported by SUSTAIN FORTE showing 2.1% HbA1c reduction). Lilly's ad includes a small footnote: "Ozempic 2mg not available at time of study." Novo claims this is misleading because it compares Mounjaro's highest dose to Ozempic's lower dose, omitting the more effective 2mg dose. 3. **Foundayo (orforglipron) vs. Rybelsus (oral semaglutide)**: Lilly's press release in Sept 2025 claimed orforglipron was superior to "oral semaglutide" based on the ACHIEVE-3 trial. But ACHIEVE-3 compared orforglipron (12mg and 36mg) to Rybelsus 7mg and 14mg (lower diabetes doses), not the highest 25mg dose approved for weight loss as the **Wegovy tablet** (OASIS 4 trial) in December 2025. 4. **FDA approvals / timelines mentioned**: - **Wegovy 7.2 mg** approved in **March 2026** (based on STEP UP trial). - **Wegovy tablet (oral semaglutide 25 mg)** approved in **December 2025** (based on OASIS 4 trial). - **Ozempic pill (Rybelsus rebranded)** approved/rebranded in **May 2026**. - **Foundayo (orforglipron)** approved (by early 2026, since the complaint says "once Foundayo also received FDA approval" when discussing Novo Nordisk removing its "only FDA-approved GLP-1 RA pill for weight loss" claim). Let's check the status of the preliminary injunction. The complaint was filed on July 21, 2026. On July 24, 2026, Novo Nordisk filed a motion for a preliminary injunction. Let's see if we can search for the scheduled dates for the preliminary injunction hearing or response. Let's do a web search.

This is great. So, the MobiHealthNews article explicitly states: "The court is scheduled to consider the motion on Aug. 17." Let's see if we can find more details about this August 17, 2026, date. It matches our watch `019fa2b2-30f2-7453-a82b-71b8bf637885` (Preliminary Injunction Decision in Novo Nordisk v. Eli Lilly False Advertising Lawsuit), which had a description: "Novo Nordisk plans to file a formal motion for a preliminary injunction on August 17, 2026, to stop Eli Lilly from running comparative ads for Zepbound and Mounjaro." Wait, actually, Novo Nordisk *filed* the motion early on **July 24, 2026**, and the court is scheduled to consider it on **August 17, 2026**! This means the fire date is still in the future (August 17, 2026). Let's keep this watch open, but we can update it or record that the motion has been filed on July 24, 2026, and the hearing/consideration is set for August 17, 2026. Now, let's search for "Eli Lilly lawsuit Sandoz Hybio tirzepatide" to see if there is any lawsuit filed. Wait, let's search for patent litigation filed by Eli Lilly in late July or August 2026. Let's run a web search for: `"Eli Lilly" AND "Sandoz" AND "tirzepatide" AND "District Court"` or `"Eli Lilly" AND "Hybio" AND "tirzepatide" AND "District Court"`. Or we can search for `"tirzepatide" AND "patent infringement"` to see if any new cases have popped up in Indiana or Delaware district courts. Let's run a web search.

Let's fetch the Velox Peps guide: `https://veloxpeps.com/guides/tirzepatide-generic-anda-2026/` to see if there is any update on the patent infringement lawsuit. Let's run a web_fetch.

Ah, the search budget is spent. That is perfectly fine, we have an enormous amount of high-quality, primary source evidence, including the full text of Novo Nordisk's false advertising complaint against Eli Lilly from July 21, 2026, and details on Sandoz's ANDA filing from June 29, 2026. Let's carefully review the active watches and see which ones we can resolve, keep open, or update. 1. **Viking Therapeutics Q2 2026 Earnings Call and Corporate Update** (id: `019fa2b2-744d-7bfb-aced-a1ebd4550e8c`): - This watch has fired! Viking reported its Q2 2026 financial results and gave a corporate update on July 29, 2026. - What happened: Viking's CEO Brian Lian reported that Phase 3 VANQUISH-1 (subcutaneous VK2735 in obesity, ~4,500 patients) and Phase 3 VANQUISH-2 (subcutaneous VK2735 in obesity with type 2 diabetes, ~1,000 patients) are fully enrolled and proceeding as planned. - Oral VK2735 Phase 3 obesity trial initiation is still expected in **4Q26**. - VK2735 Phase 1 maintenance dosing study results are expected **later this quarter (3Q26)**. - Cash balance is $502 million. Net loss widened to $128M. - Let's record an event for this watch and resolve it. 2. **Preliminary Injunction Decision in Novo Nordisk v. Eli Lilly False Advertising Lawsuit** (id: `019fa2b2-30f2-7453-a82b-71b8bf637885`): - Novo Nordisk filed the lawsuit on July 21, 2026 (Case 3:26-cv-09027-ZNQ-RLS, D.N.J.). - Novo Nordisk filed a motion for a preliminary injunction on July 24, 2026. - The court is scheduled to consider the motion on **August 17, 2026**. - This watch is ongoing or one-shot with a fire date of August 31, 2026. Since the decision has not been made yet (it's scheduled for August 17), we should keep this watch open, but we can record an event showing the motion was filed on July 24, 2026, and the court will consider it on August 17, 2026. Wait! Let's see if we can record an event with `resolves: false` to keep it open, or just let it fire later. The tool `record_event` says `resolves: false` keeps it open. Let's record the event that the motion was filed. 3. **Eli Lilly Patent Infringement Lawsuits against Sandoz and Hybio (Tirzepatide ANDAs)** (id: `019f7ea7-f526-7381-8937-a067d41f8465`): - Sandoz's ANDA was accepted on June 29, 2026. - Hybio's ANDA was accepted on June 30, 2026. - Eli Lilly has a 45-day window from acceptance to file patent infringement lawsuits to trigger the automatic 30-month FDA approval stay. This window ends around August 13-14, 2026. - Since we didn't find any lawsuit filed yet (as of August 3, 2026, which is within the 45-day window), this watch is still open and we should keep tracking it. 4. **Novo Nordisk Q2 2026 Earnings and Oral Wegovy Retention Rates** (id: `019f5a99-5df2-79a6-a479-7bd5b7c92acd`): - This is scheduled for August 5, 2026. Today is August 3, 2026. So this has not happened yet. We keep it open. Let's write notes for our findings. We have three key areas of updates: 1. **Novo Nordisk v. Eli Lilly False Advertising Lawsuit**: - Update the existing note `novo-sues-lilly-false-advertising-glp1-2026` (Novo Nordisk Sues Eli Lilly Over "False and Misleading" GLP-1 Comparative Ads). - Let's review the details of the complaint we fetched: Case 3:26-cv-09027-ZNQ-RLS filed on July 21, 2026, in D.N.J. - The complaint details the specific advertisements: - Zepbound vs. Wegovy: compares Zepbound 10mg/15mg (50 lbs lost) to Wegovy 1.7mg/2.4mg (33 lbs lost) based on SURMOUNT-5 (open-label). Omit Wegovy 7.2 mg (approved March 2026, STEP UP trial showed 47 lbs lost, clinically consistent with Zepbound). - Mounjaro vs. Ozempic: compares Mounjaro 15mg (2.3% A1c reduction) to Ozempic 1mg (1.9% reduction) based on SURPASS-2. Omit Ozempic 2 mg (approved 2022, SUSTAIN FORTE showed 2.1% reduction). - Orforglipron (Foundayo) vs. Oral Semaglutide (Rybelsus): press release in Sept 2025 claimed superiority based on ACHIEVE-3 (compared to Rybelsus 7mg/14mg, not the Wegovy tablet 25mg approved in Dec 2025). - Novo Nordisk filed a motion for preliminary injunction on July 24, 2026, with the court scheduled to consider it on August 17, 2026. 2. **Viking Therapeutics Q2 2026 Earnings and Pipeline Update**: - Update the existing note `viking-therapeutics-vktx-ma-target-oral-vk2735-2026` (Viking Therapeutics Diversifies Obesity Pipeline: Refines Timelines Ahead of Q2 2026 Earnings). - Details: reported July 29, 2026. Phase 3 VANQUISH-1 (subcutaneous VK2735 in obesity, ~4,500 patients) and Phase 3 VANQUISH-2 (subcutaneous VK2735 in obesity with T2D, ~1,000 patients) are fully enrolled. - Oral VK2735 Phase 3 trial initiation expected in 4Q26. - VK2735 subcutaneous Phase 1 maintenance dosing study results expected "later this quarter" (3Q26). - Phase 1 single ascending dose trial of amylin receptor agonist VK3019 initiated in Q2 2026. - Financials: cash of $502 million. R&D increased to $115.8M, net loss widened to $128.0M ($1.10 per share). 3. **Generic Tirzepatide ANDA Filings (Sandoz and Hybio)**: - Update the existing note `generic-tirzepatide-anda-sandoz-hybio-2026` (FDA Accepts Generic Tirzepatide ANDAs from Sandoz and Hybio, Launching the GLP-1 Generic Era). - Details: Sandoz's ANDA accepted on June 29, 2026; Hybio's accepted on June 30, 2026. - Earliest possible approval is May 2027 (when Mounjaro's 5-year NCE exclusivity expires). - Eli Lilly has a 45-day window to file patent-infringement litigation to trigger an automatic 30-month stay of approval, which expires around August 13-14, 2026. - Sandoz's candidate was developed entirely in-house. Lilly holds patents covering the molecule, autoinjector device, and formulations extending into the mid-2030s (e.g., U.S. Patent No. 11,357,820 on formulation expires June 14, 2039; U.S. Patent No. 9,474,780 on dual GIP/GLP-1 receptor agonist expires January 5, 2036). Let's check the slugs of the notes to update: - `novo-sues-lilly-false-advertising-glp1-2026` - `viking-therapeutics-vktx-ma-target-oral-vk2735-2026` - `generic-tirzepatide-anda-sandoz-hybio-2026` This is extremely precise! Let's write the notes first. Wait, let's write the notes one by one, starting with `novo-sues-lilly-false-advertising-glp1-2026`. I will state my intent and call `write_note`.

This is excellent. Now let's write the note for Viking Therapeutics: `viking-therapeutics-vktx-ma-target-oral-vk2735-2026`. I will state my intent and call `write_note`.

This is fantastic. Now let's write the note for the generic tirzepatide ANDA filings: `generic-tirzepatide-anda-sandoz-hybio-2026`. I will state my intent and call `write_note`.

This is outstanding. All three notes have been successfully updated with concrete, primary-sourced findings. Now, let's look at the threads/watches to resolve or record. 1. **Viking Therapeutics Q2 2026 Earnings Call and Corporate Update** (id: `019fa2b2-744d-7bfb-aced-a1ebd4550e8c`): - We need to call `resolve_thread` for this watch because it has fired and we have fully documented the outcomes in our note `viking-therapeutics-vktx-ma-target-oral-vk2735-2026`. - Let's call `resolve_thread` for `019fa2b2-744d-7bfb-aced-a1ebd4550e8c`. Let's state our intent and do it.

2. Let's record an event for the preliminary injunction watch `019fa2b2-30f2-7453-a82b-71b8bf637885` (Preliminary Injunction Decision in Novo Nordisk v. Eli Lilly False Advertising Lawsuit). - The watch is ongoing/one-shot with a fire date of August 31, 2026. - We should record that Novo Nordisk filed the formal motion for a preliminary injunction on July 24, 2026, and the court is scheduled to consider the motion on August 17, 2026. - This keeps the watch open (`resolves: false`) until the court actually makes a decision. - Let's call `record_event` with `resolves: false`. Let's state our intent and do it.

Let's double-check if there are any other watches we should record or update. We have: - `019f7ea7-f526-7381-8937-a067d41f8465` (Eli Lilly Patent Infringement Lawsuits against Sandoz and Hybio (Tirzepatide ANDAs)) -> This expires around August 15, 2026. Since Lilly has not filed yet, we keep it open. - `019f5a99-5df2-79a6-a479-7bd5b7c92acd` (Novo Nordisk Q2 2026 Earnings and Oral Wegovy Retention Rates) -> This is scheduled for August 5, 2026. We keep it open. - `019f5a99-679f-7247-9705-ad3f8b2ad4cd` (Viking Therapeutics Oral VK2735 Phase 3 Trial Initiation) -> Scheduled for 4Q26. We keep it open. - `019f7ea7-feb9-7623-b860-3dba62bb1602` (Viking Therapeutics VK2735 Phase 1 Maintenance Dosing Results) -> Scheduled for 3Q26 ("later this quarter" per Q2 earnings call). We keep it open. Wait, are there any other new watches we should register based on what we've discovered? We found that: 1. **Wegovy 7.2 mg** was approved in **March 2026**. 2. **Wegovy tablet (oral semaglutide 25 mg)** was approved in **December 2025** (based on OASIS 4 trial). 3. **Foundayo (orforglipron)** was approved (by early 2026). 4. **Ozempic pill (Rybelsus rebranded)** was approved/rebranded in **May 2026**. These are all past events, so no new watches are needed for them. Let's do a quick final check of our memory and workspace. Since we are in a research cycle, we should write down key facts in our long-term memory if needed, but wait, the guidelines say: "- Long-term memory: /var/lib/hey-lefty/notes/9a44a098-76c7-4569-9018-23a27f9ebd7f/019e46ac-88a3-731f-aeee-a2d9443452d6/memory/MEMORY.md (write important facts here)" Let's read the MEMORY.md file first to see if it exists and what's in it, then we can write to it if needed. Wait, we don't have to unless we want to keep long-term memory updated. Let's see if we have access to it or if it's managed automatically. Actually, let's just make sure we finish the cycle properly. Wait, the prompt says "Call finish_cycle to end the research cycle." Let's call `finish_cycle`. I will state my intent and call the tool.

The research cycle is now complete. Here is a summary of the findings and updates from this cycle: ### 1. Novo Nordisk v. Eli Lilly False Advertising Lawsuit * **Action Taken**: Updated note `novo-sues-lilly-false-advertising-glp1-2026`. * **Key Findings**: On **July 21, 2026**, Novo Nordisk filed a comprehensive false advertising lawsuit (Case 3:26-cv-09027-ZNQ-RLS, D.N.J.) against Eli Lilly under the Lanham Act. Novo Nordisk followed this with a motion for a preliminary injunction on **July 24, 2026**, which the court is scheduled to consider on **August 17, 2026**. * **Details of Complaint**: * **Zepbound vs. Wegovy**: Novo claims Lilly's ads are deceptive because they compare Zepbound 10mg/15mg (50 lbs average loss) to Wegovy 1.7mg/2.4mg (33 lbs average loss) using outdated open-label **SURMOUNT-5** data. This omits **Wegovy 7.2 mg** (approved in **March 2026**), which demonstrated an average weight loss of **18.8% (~47 pounds)** in the double-blind **STEP UP** trial—clinically consistent with Zepbound's highest dose. * **Mounjaro vs. Ozempic**: Lilly's ads compare Mounjaro 15 mg (2.3% HbA1c reduction) to Ozempic 1 mg (1.9% reduction) using 5-year-old **SURPASS-2** data, omitting the higher **Ozempic 2 mg** dose (approved in 2022), which achieved a **2.1%** reduction in the **SUSTAIN FORTE** trial. * **Foundayo vs. Rybelsus**: Novo cites Lilly's press release in September 2025 claiming orforglipron (Foundayo) was superior to oral semaglutide based on **ACHIEVE-3** (using Rybelsus 7mg/14mg), omitting the highest **25 mg Wegovy tablet** (approved in **December 2025** based on the **OASIS 4** trial). ### 2. Viking Therapeutics Pipeline and Earnings Update * **Action Taken**: Updated note `viking-therapeutics-vktx-ma-target-oral-vk2735-2026` and resolved the corresponding watch thread. * **Key Findings**: Viking reported Q2 2026 results on **July 29, 2026**. * **Phase 3 SC VK2735**: Both **VANQUISH-1** (obesity, ~4,500 patients) and **VANQUISH-2** (obesity + T2D, ~1,000 patients) trials are **fully enrolled** and proceeding as planned. * **Oral VK2735**: On track to initiate its Phase 3 clinical trial in **4Q26**. * **Maintenance Dosing Study**: Results from the Phase 1 subcutaneous maintenance dosing study are expected **later in 3Q26**. * **New Amylin Program**: Viking initiated a Phase 1 trial for **VK3019**, an amylin receptor agonist, during Q2 2026. * **Financials**: Ending cash balance of **$502 million** (down from $706 million at year-end 2025). Q2 net loss widened to **$128.0 million** ($1.10/share) due to scaling Phase 3 R&D costs ($115.8 million). ### 3. Sandoz and Hybio Generic Tirzepatide ANDAs * **Action Taken**: Updated note `generic-tirzepatide-anda-sandoz-hybio-2026`. * **Key Findings**: Sandoz's ANDA was accepted on **June 29, 2026**, and Hybio's on **June 30, 2026**, for generic tirzepatide autoinjectors. * **Exclusivity Expiry**: The earliest possible FDA approval is **May 2027** when Lilly's 5-year NCE exclusivity expires. * **30-Month Stay Deadline**: Eli Lilly has a 45-day window from acceptance to file patent infringement lawsuits to trigger an automatic 30-month stay of FDA approval. This deadline is **mid-August 2026** (approximately August 13–14, 2026). * **Lilly's Patent Moat**: Lilly holds key patents covering the compound (U.S. Patent No. 9,474,780, expiring **January 5, 2036**) and formulation (U.S. Patent No. 11,357,820, expiring **June 14, 2039**), which will likely delay actual generic launch until the mid-to-late 2030s. ### Active Watches Updated * **Resolved**: `Viking Therapeutics Q2 2026 Earnings Call and Corporate Update` (id: `019fa2b2-744d-7bfb-aced-a1ebd4550e8c`). * **Updated / Event Recorded**: `Preliminary Injunction Decision in Novo Nordisk v. Eli Lilly False Advertising Lawsuit` (id: `019fa2b2-30f2-7453-a82b-71b8bf637885`) now tracks the upcoming **August 17, 2026** court consideration date.